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Abstract
Classification of pituitary adenomas is still changing and not completely satisfying. Various 
types of hormones, prehormonal substances, and transcription factors are detected in 
pituitary adenomas. Monohormonal secretion in pituitary adenomas is frequent, notably 
prolactin secretion. Secretion of more than one hormone normally originating from the 
same adenohypophyseal cell lineage is well known, classically GH-PRL and FSH-LH. Other 
combinations of hormonal secretion are reported; they are sometimes underestimated. 
Plurihormonal secretion in pituitary adenomas, which is secretion of hormones that are nor-
mally originating from different adenohypophyseal cell lineages, is usually underestimated 
and in most cases remains subclinical. An immunohistochemical study of all pituitary hor-
mones and prehormonal substances, as demonstrating transcription factors, is not always 
available; it is frequently not performed. This chapter aims to show the underestimated and 
vague areas of pituitary adenomas and to emphasize the importance of immunohistochemi-
cal studies in the diagnosis and prediction of clinical outcomes of these adenomas.
Keywords: pituitary adenoma, monohormonal adenoma, plurihormonal adenoma, 
atypical adenoma, aggressive adenoma, high-risk adenoma, pituitary neuroendocrine 
tumor, pituitary carcinoma, immunohistochemical studies
1. Introduction
Classification of pituitary adenomas is still changing; it requires morphological and hormonal 
immunohistochemical assessments. These adenomas reveal various histopathological pat-
terns and tinctorial properties which proved to be unreliable and do not always correlate with 
the functional or immunohistochemical findings.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The 3rd WHO classification of adenohypophyseal cell lineage in pituitary adenomas in 2004 
was based on functional properties using histological study, immunohistochemical proper-
ties, ultrastructural features, biochemical imaging, and surgical findings [1].
The 4th WHO classification of pituitary adenomas in 2017 [2] is mostly based on the adeno-
hypophyseal cell lineage designation according to immunohistochemical markers such as 
pituitary hormones and pituitary-specific transcription factors. Comparison between the 3rd 
and the 4th WHO classification is shown in Table 1.
Some transcription factors and cofactors have a known role in the differentiation of pituitary 
cell lineages [2–4], e.g., PIT1 (pituitary transcription factor 1 for growth hormone also known 
as POUF1 [3]), ER-alpha (nuclear estrogen receptor alpha), SF1 (splicing factor 1), and TPIT 
(transcription factor for pituitary corticotroph cell lineage).
Many adenomas secrete one hormone; though secretion of more than one hormone is well 
documented, the following combinations of hormones are reported [1, 3]:
• GH (growth hormone) and PRL (prolactin)
• FSH and LH
• FSH, LH, TSH, and a-SU (alpha subunit is identical for gonadotropin hormones and TSH)
Tumor cells in these cases are originating from the same cell lineage.
2. Value of immunohistochemical studies in pituitary adenomas
Immunostaining is achieving a progressively important role in pituitary adenomas. The 4th 
WHO classification of pituitary adenomas in 2017 [2] is mostly based on the adenohypophyseal 
cell lineage designation according to immunohistochemical markers for the main secreting hor-
mones; for example, the new designation “somatotroph adenoma” defines a group of tumors 
that are derived from a PIT1 lineage and secrete growth hormone; this replaces the former term 
growth hormone-producing adenoma as previously designed in the 3rd WHO classification [1].
Immunohistochemical markers allow for differentiation between clinically relevant histo-
logical subtypes that was mainly ultrastructural features. Electron microscopy is now rarely 
The 3rd WHO classification of pituitary adenomas [1] The 4th WHO classification of pituitary adenomas [3]
Growth hormone producing adenoma Somatotroph adenoma
Prolactin producing adenoma Lactotroph adenoma
Thyrotropin producing adenoma Thyrotroph adenoma
ACTH producing adenoma Corticotroph adenoma
Gonadotropin producing adenoma Gonadotroph adenoma
Null cell adenoma Null cell adenoma
Plurihormonal adenoma Plurihormonal and double adenoma
Table 1. Comparison between the 3rd and the 4th WHO classification of pituitary adenomas.
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used to classify pituitary tumors; it is not necessary for the routine investigation of pituitary 
tumors. However, ultrastructural evaluation may be useful in the differential diagnosis of 
undifferentiated tumors and in a very limited number of adenoma subtypes, such as pluri-
hormonal PIT1-positive adenoma [2].
Transcription factors for pituitary cell lineages are as follows [3, 4]:
• Somatotroph lineage: PIT1, which is a pituitary transcription factor 1 for growth hormone 
also known as POUF1.
• Lactotroph differentiation: PIT1 and ER-alpha.
• Thyrotroph differentiation: PIT1 and GATA2. GATA2 is a nuclear protein regulating gene 
expression.
• Gonadotroph differentiation: GATA2 and SF1. SF1 is splicing factor 1, also known as zinc 
finger protein 162.
• Corticotroph cell lineage: TPIT.
3. Plurihormonal pituitary adenomas
Plurihormonal pituitary adenomas are defined as tumors that show immunoreactivity for 
more than one hormone that cannot be explained by normal cytophysiology or devel-
opmental mechanism [5]. They can be monomorphous, consisting of a single cell type 
producing two or more hormones, or plurimorphous, consisting of two or more different 
cell lineages.
Plurihormonality is reported in the literature; it is estimated rare in most studied series while 
they are more frequent in other series [5, 6–8]. Most plurihormonal adenomas are silent [2]. 
Various combinations are described in the literature in the studied series:
• PRL and LH; PRL and TSH [7]
• GH and ACTH [9–11]
• PRL and ACTH [5, 7, 12, 13]
• ACTH, LH, and TSH [7]
• PRL, LH, FSH, and TSH [7]
• GH, PRL, TSH, and a-SU [5]
• GH, PRL, and ACTH [7, 14]
• GH, PRL, TSH, FSH, and aSU [15]
Other less common combinations are also published [5]. Original examples of plurihormonal 
adenomas in the author series [7] are shown in Figures 1–3.
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Figure 2. (A) Pituitary adenoma revealing a pseudoglandular and microcystic structure (x400, HE stain). (B). Prolactin 
secretion in some tumor cells (x400, PRL-antibody, Dako). (C) TSH secretion in the same tumor, apparently in different 
cells than prolactin secretion (x400, TSH-antibody, Dako). (D) FSH secretion in the same tumor, apparently in different 
cells than prolactin and TSH secretion (x400, FSH-antibody, Dako).
Figure 1. (A) Pituitary adenoma revealing a trabecular and nested structure (HE stain, x200), composed of two distinct 
types of cells. (B) ACTH secretion in the same adenoma (x400, ACTH-antibody, Dako). (C) Prolactin secretion in the 
same adenoma (x400, PRL-antibody, Dako). Positive stain is demonstrated in different cells than cells positive for ACTH. 
Detection of other pituitary hormones was negative.
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Some of the secretions might remain subclinical and only detected by immunohistochemical 
studies.
It was noted that half of the somatotroph adenomas, particularly densely granulated adeno-
mas, secrete other hormones; these hormones are not clinically relevant [1, 3].
A combination of hormone secretion was also reported in double pituitary adenoma base on 
two separate tumors on MRI imaging or histopathologic examination [5].
Pituitary adenomas with the combination of different hormone groups from the same cell 
lineage (GH and prolactin or FSH and LH) are relatively common, but true plurihormonal 
adenomas with immunoreactivities that cross the cytogenetic lineage are rare in most series 
as “in Refs. [5, 6, 13].”
The challenging points are:
1. How many cells that are positive for each type of hormones or pituitary transcription fac-
tors can allow the diagnosis of plurihormonal adenoma?
2. The new definition of the null cell adenoma requires the demonstration of immunonega-
tivity for pituitary transcription factors and adenohypophyseal hormones [2, 16]; however, 
does the observation of rare or few positive cells for immunohistochemical markers allow 
to rule out the diagnosis of null cell adenoma?
4. Hormone secretion and prognosis of pituitary adenomas
Many studies tried to find out the criteria for predicting the prognosis and development of 
pituitary adenomas; though most of them have benign outcomes, others might have adverse 
outcomes and be able to invade locally, resist conventional therapy, or might recur or metas-
tasize [2].
Figure 3. (A) Crooke cell adenoma (x400, HE stain). (B) ACTH secretion in the same Crooke cell adenoma (x400, ACTH-
antibody, Dako). (C). Prolactin secretion in the same crook cell adenoma, apparently positive in the same cells as ACTH 
(x400, PRL-antibody, Dako). Detection of other pituitary hormones was negative.
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The following question is raised: Is any relationships exist between hormone secretion and 
prognosis of pituitary adenomas?
4.1. Potentially “aggressive pituitary adenoma”
Certain subtypes of pituitary adenomas are found tending to show more aggressive clini-
cal behavior and designed by some authors as aggressive adenomas [2]; these are: sparsely 
granulated somatotroph adenoma (SGSA), lactotroph macroadenoma in men, Crooke cell 
adenoma, silent corticotroph adenoma, and plurihormonal PIT1-positive adenoma (previ-
ously called silent subtype 3 adenomas [1–3, 5]). It is also reported that pituitary adenomas 
found in MEN1 (multiple endocrine neoplasia type 1) tend to be plurihormonal and more 
aggressive [12].
4.2. “High-risk pituitary adenoma”
The defined criteria for this adenoma in the last 4th WHO classification for pituitary adeno-
mas are, as “in Refs. [2, 3, 17]”:
• Rapid growth
• Radiological invasion
• High Ki-67 proliferation index more than 3%
This adenoma tends to predict recurrence and resistance to conventional therapy [2].
It is not clear whether all potentially “aggressive pituitary adenomas” are “high-risk adeno-
mas,” as the first term depends on hormone secretion, while the second term depends on 
clinical and radiological data plus the immunohistochemical study for Ki-67 proliferation 
index. P53 is not considered as an independent risk factor [2].
A high risk adenoma with histological signs of aggressiveness is shown in Figure 4.
4.3. “Atypical adenoma”
The term “atypical adenoma” was previously used in the 3rd WHO classification [1]; it is 
defined by a high mitotic index, Ki-67 mitotic index more than 3%, and strong nuclear P53 
staining. This term is no more used in the 4th classification [2], as it did not prove any util-
ity. Atypical adenoma is replaced by the definition of “high-risk adenoma.” Strong positive 
nuclear expression of P53 is not proved to be an independent factor of high-risk adenoma [2].
4.4. Plurihormonality and prognosis
Plurihormonal PIT1-positive adenomas are aggressive in terms of their size, growth rate, 
and invasiveness, with cavernous sinus invasion occurring in 67% of cases and 31% rate of 
recurrence [5].
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4.5. Pituitary carcinoma
The only conclusive criterion of malignancy is actually metastasis. The last WHO classification 
of pituitary adenomas strictly defined pituitary carcinoma as a tumor of adenohypophyseal 
cells that metastasizes craniospinally or is associated with systemic metastasis. This definition 
is independent of the histological appearance; as histologically, about 60% of primary tumors 
have features of a conventional adenoma [2, 18].
Pre-metastatic lesions and metastases can be hormonally active or clinically nonfunctioning. 
There are no clinical or biochemical features specific to an adenoma that will metastasize [18]. 
No confirmed relationship is demonstrated between non-secreting adenoma, plurihormonality, 
and malignancy; though, plurihormonal PIT1-positive carcinomas have also been reported [18].
4.6. Pituitary neuroendocrine tumor (PitNET)
This term is recently proposed in 2017 for pituitary adenoma by the International Pituitary 
Pathology Club to explain the highly variable clinical impact of pituitary adenomas on 
patients and the poor reproducibility of the actual predictive markers [19] though the margins 
are not clear between pituitary adenomas and neuroendocrine tumors.
Figure 4. Aggressive and high-risk pituitary adenoma revealing vascular invasion and mitotic figures (x200, HE stain). 
It demonstrated immunonegativity for hormone secretion.
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Pituitary carcinomas are demonstrated positive for neuroendocrine differentiation like syn-
aptophysin and chromogranin A [18].
5. Necessity of hormone detection by immunohistochemical studies
5.1. Questions frequently raised when we have a case of pituitary adenoma
Pathologists and clinicians might ask the following questions:
1. Is it necessary to make histological study to every pituitary adenoma?
2. Is it necessary to demonstrate hormonal production in all pituitary adenomas studied by 
pathologists?
3. How many antibodies should a pathologist use to study this adenoma?
4. Which antibodies have clinical utility for treatment and prognostic prediction?
5. Can we predict the aggressiveness of a pituitary adenoma before that it becomes clinically 
and radiologically aggressive?
5.2. Importance of immunohistochemical studies
We might find answers on the previous questions in the following findings:
• Classification of pituitary adenomas requires morphological and hormonal immunohisto-
chemical assessment [2, 3].
• Nonfunctional adenomas, with no hormone detection in the serum, are not necessarily 
nonproducing adenomas. Detection of hormonal production by immunostaining leads to 
term them “silent adenomas” [2, 3]. Some authors recently proposed to term them “poorly 
differentiated Pit-1 lineage adenomas” [20].
• Immunostaining is important to diagnose some of the potentially “aggressive adenomas” 
subtypes as mentioned before.
• Detection of PIT1 and hormonal production is important for the diagnosis of plurihor-
monal PIT1-positive pituitary adenomas (previously called silent subtype 3 adenomas) 
that are considered as potentially “aggressive adenoma” [2, 5].
• Detection of the somatostatin receptor by immunohistochemistry may be a useful predictor 
of treatment response, as SGSAs are less responsive to somatostatin antagonists and may 
require treatment with the GH receptor antagonist pegvisomant [21].
• Demonstration of immunonegativity for hormones and transcription factors, especially 
Pit-1, is important for the differential diagnosis between silent adenomas and null cell ade-
noma, as the latter has good prognosis. Some silent adenomas, notably silent corticotroph 
adenoma and plurihormonal PIT1-positive adenoma (previously called silent subtype 3 
adenomas), are considered potentially “aggressive adenomas” [2, 17, 22].
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• Demonstration of NSE, chromogranin A and synaptophysin helps to diagnose PitNET and 
might predict more aggressive potential even before that the tumor comes clinically and 
radiologically aggressive.
5.3. Recommended antibodies for the diagnosis and prediction
It is important to demonstrate hormone production, transcription factors for functional dif-
ferentiation, and proliferation index that indicate prediction. Practically, the following immu-
nohistochemical stains are recommended in studying a pituitary adenoma as they cover wide 
area of diagnosis and prediction:
• GH, prolactin, TSH-beta, ACTH, FSH-beta, LH-beta, and alpha-SU to make an accurate 
classification of the studied pituitary adenoma.
• Pit-1 and TPIT transcription factors and ER-alpha are recommended when there is immu-
nonegativity for pituitary hormones, to rule out potentially aggressive silent adenomas. 
SF1, the transcription factor for gonadotroph cell lineage does not seem to have prognostic 
importance, as gonadotroph adenomas are usually not aggressive.
• Ki-67 proliferation index, for the demonstration of “high-risk adenomas.”
• Chromogranin A and synaptophysin diagnose PitNET that might predict more aggressive 
behavior.
• P53 is not an independent risk factor of aggressiveness; so it is not necessary to demonstrate it.
6. Conclusions
Immunohistochemical studies have increasing importance in pituitary adenomas. Dem-
onstration of hormones, some transcription factors and cofactors for functional differentiation, 
and proliferation index have important roles in the classification, prediction, and treatment of 
these adenomas, as demonstration of neuroendocrine differentiation.
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